Atherosclerosis
Volume 183, Issue 2 , Pages 268-274 , December 2005

Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction

  • David E. Mosedale

      Affiliations

    • Department of Medicine, University of Cambridge, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK
    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1480 364470; fax: +44 1480 364902.
    • ,
  • Duncan J. Smith

      Affiliations

    • Department of Medicine, University of Cambridge, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK
    • ,
  • Sri Aitken

      Affiliations

    • Department of Medicine, University of Cambridge, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK
    • ,
  • Peter M. Schofield

      Affiliations

    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • ,
  • Sarah C. Clarke

      Affiliations

    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • ,
  • Duncan McNab

      Affiliations

    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • ,
  • Hester Goddard

      Affiliations

    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • ,
  • Catharine R. Gale

      Affiliations

    • MRC Environmental Epidemiology Unit, Southampton General Hospital, Southampton SO16 6YD, UK
    • ,
  • Christopher N. Martyn

      Affiliations

    • MRC Environmental Epidemiology Unit, Southampton General Hospital, Southampton SO16 6YD, UK
    • ,
  • Hugh W.L. Bethell

      Affiliations

    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • ,
  • Caryl Barnard

      Affiliations

    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • ,
  • Sarah Hayns

      Affiliations

    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • ,
  • Claire Nugent

      Affiliations

    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • ,
  • Annik Panicker

      Affiliations

    • Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
    • ,
  • David J. Grainger

      Affiliations

    • Department of Medicine, University of Cambridge, Box 157, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK

Received 6 August 2004 ,Revised 1 November 2004 ,Accepted 17 November 2004.

References 

  1. Rollins BJ. Chemokines. Blood. 1997;90:909–928
  2. Kitaura M, Nakajima T, Imai T, et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor CC chemokine receptor 3. J Biol Chem. 1996;271:7725–7730
  3. Morita A, Shimosako K, Kikuoka S, et al. Development of a sensitive enzyme-linked immunosorbent assay for eotaxin and measurement of its levels in human blood. J Immunol Meth. 1999;226:159–167
  4. Weiss L, Si-Mohamed A, Giral P, et al. Plasma levels of monocyte chemoattractant protein- 1 but not those of macrophage inhibitory protein-1 alpha and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis. 1997;176:1621–1624
  5. Nakamura H, Weiss ST, Israel E, et al. Eotaxin and impaired lung function in asthma. Am J Respir Crit Care Med. 1999;160:1952–1956
  6. Dawson TC, Kuziel WA, Osahar TA, Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 1999;143:205–211
  7. Gosling J, Slaymaker S, Gu L, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103:773–778
  8. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275–281
  9. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894–897
  10. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121–1127
  11. Seino Y, Ikeda U, Takahashi M, et al. Expression of monocyte chemoattractant protein-1 in vascular tissue. Cytokine. 1995;7:575–579
  12. Takeya M, Yoshimura T, Leonard EJ, Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol. 1993;24:534–539
  13. Haley KJ, Lilly CM, Yang JH, et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation. 2000;102:2185–2189
  14. Matsumori A, Furukawa Y, Hashimoto T, et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol. 1997;29:419–423
  15. Hokimoto S, Ogawa H, Saito T, et al. Increased plasma antigen levels of monocyte chemoattractant protein-1 in patients with restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J. 2000;64:831–834
  16. Cipollone F, Marini M, Fazia M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vase Biol. 2001;21:327–334
  17. Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 1998;97:1136–1143
  18. Probstfield JL, Byington RP, Egan DA, et al. Methodological issues facing studies of atherosclerotic change. Circulation. 1993;87:II74–II81
  19. Gale CR, Ashurst HE, Powers HJ, Martyn CN. Antioxidant vitamin status and carotid atherosclerosis in the elderly. Am J Clin Nutr. 2001;74:402–408
  20. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest. 1983;71:1854–1866
  21. Inadera H, Egashira K, Takemoto M, Ouchi Y, Matsushima K. Increase in circulating levels of monocyte chemoattractant protein-1 with aging. J Interferon Cytokine Res. 1999;19:1179–1182
  22. Economou E, Tousoulis D, Katinioti A, et al. Chemokines in patients with ischaemic heart disease and the effect of coronary angioplasty. Int J Cardiol. 2001;80:55–60
  23. Hernandez C, Lecube A, Barbera G, et al. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Med Sci Monit. 2003;9:CR114–CR119
  24. Koh KK, Son JW, Ahn JY, et al. Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. Cor Artery Dis. 2001;12:305–311
  25. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728–2735
  26. Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension. 2002;40:687–693

PII: S0021-9150(05)00235-2

doi: 10.1016/j.atherosclerosis.2004.11.028

Atherosclerosis
Volume 183, Issue 2 , Pages 268-274 , December 2005

Article Tools

* Image Usage & Resolution